Study summary
A dual PPAR pill produced liver-test responses in half of patients
51%biochemical response at 52 weeks, vs 4% with placebo
What was tested
Elafibranor, a PPAR-alpha/delta agonist, against placebo, added to ursodiol for primary biliary cholangitis with inadequate response.
What they found
- Biochemical response was 51% vs 4%.
- Alkaline phosphatase normalized in 15% vs 0%.
- Itching did not improve significantly more than with placebo.
What it means
The other new second-line option; long-term studies are testing whether it prevents cirrhosis and liver failure.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.